Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23946313.
- Also identified by DOI 10.1212/WNL.0b013e3182a55ea5 and PMC identifier 3795600.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We previously reported clinical improvement, increase in putamen [(18)F]-dopa uptake on PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following chronic intraputaminal delivery of glial cell line-derived neurotrophic factor (GDNF) in idiopathic Parkinson disease (PD).(1-3) We now provide clinical and PET evidence of persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a patient with PD. This is a single-case observational study, providing Class IV evidence.
Medical subject headings
- Antiparkinson Agents
- Glial Cell Line-Derived Neurotrophic Factor
- Parkinson Disease
- Putamen